The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of risdiplam within its marketing authorisation for treating spinal muscular atrophy in children and adults.
I also felt it helpful to write and advise you of the draft timelines we have planned for your information. The appraisal is expected to start in approximately late August 2020 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early November 2020.
For information, these timings are based on a delay for this topic due to COVID-19 and on a mutual agreement between the company and NICE, following a request from the company, in order to facilitate a suitably comprehensive and robust evidence submission.